DK4008782T3 - Fremgangsmåder til tilvejebringelse af enkeltstrenget rna - Google Patents
Fremgangsmåder til tilvejebringelse af enkeltstrenget rnaInfo
- Publication number
- DK4008782T3 DK4008782T3 DK21204500.9T DK21204500T DK4008782T3 DK 4008782 T3 DK4008782 T3 DK 4008782T3 DK 21204500 T DK21204500 T DK 21204500T DK 4008782 T3 DK4008782 T3 DK 4008782T3
- Authority
- DK
- Denmark
- Prior art keywords
- straindicated
- rna
- methods
- obtaining single
- obtaining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016059056 | 2016-04-22 | ||
| EP17722695.8A EP3445850B2 (en) | 2016-04-22 | 2017-04-19 | Methods for providing single-stranded rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4008782T3 true DK4008782T3 (da) | 2026-04-27 |
Family
ID=58699087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17722695.8T DK3445850T3 (da) | 2016-04-22 | 2017-04-19 | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna |
| DK21204500.9T DK4008782T3 (da) | 2016-04-22 | 2017-04-19 | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17722695.8T DK3445850T3 (da) | 2016-04-22 | 2017-04-19 | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20190153425A1 (da) |
| EP (3) | EP4008782B1 (da) |
| JP (2) | JP7000343B2 (da) |
| KR (2) | KR102565881B1 (da) |
| CN (1) | CN109072232B (da) |
| AU (1) | AU2017251983B2 (da) |
| BR (1) | BR112018069417A2 (da) |
| CA (1) | CA3020481A1 (da) |
| CY (1) | CY1124845T1 (da) |
| DK (2) | DK3445850T3 (da) |
| ES (2) | ES2900272T3 (da) |
| HR (1) | HRP20211745T1 (da) |
| HU (1) | HUE059314T2 (da) |
| IL (1) | IL262304B2 (da) |
| LT (1) | LT3445850T (da) |
| MA (1) | MA44732B1 (da) |
| MD (1) | MD3445850T2 (da) |
| MX (1) | MX2018012880A (da) |
| NZ (1) | NZ745940A (da) |
| PL (1) | PL3445850T3 (da) |
| PT (1) | PT3445850T (da) |
| RS (1) | RS62612B1 (da) |
| RU (2) | RU2760790C2 (da) |
| SG (2) | SG11201807573VA (da) |
| SI (1) | SI3445850T1 (da) |
| SM (1) | SMT202100681T1 (da) |
| WO (1) | WO2017182524A1 (da) |
| ZA (2) | ZA201805949B (da) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| JP7740988B2 (ja) * | 2019-03-12 | 2025-09-17 | バイオエヌテック エスエー | 前立腺癌のための治療用ｒｎａ |
| EP3972632A1 (en) * | 2019-05-20 | 2022-03-30 | BioNTech SE | Therapeutic rna for ovarian cancer |
| EP4010481A4 (en) * | 2019-08-09 | 2023-09-20 | Nutcracker Therapeutics, Inc. | MICROFLUIDIC DEVICE AND METHODS OF USE |
| US12570725B2 (en) | 2019-09-13 | 2026-03-10 | Duke University | ZIKA antibodies and their use |
| WO2021081437A2 (en) | 2019-10-23 | 2021-04-29 | Duke University | Compositions comprising v2 opt hiv envelopes |
| CN115087456A (zh) * | 2020-02-07 | 2022-09-20 | 奥特吉尼克斯制药公司 | 用于减少双链rna形成的离液剂 |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| AU2021250814A1 (en) | 2020-03-30 | 2022-10-13 | BioNTech SE | RNA compositions targeting Claudin-18.2 |
| SI3896160T1 (sl) * | 2020-04-17 | 2025-08-29 | Sartorius Bia Separations D.O.O. | Metoda čiščenja enoverižne rnk |
| SI3896159T1 (sl) | 2020-04-17 | 2025-08-29 | Sartorius Bia Separations D.O.O. | Metoda čiščenja enoverižne rnk z uporabo anionskega izmenjevalca |
| EP3896161A1 (en) | 2020-04-17 | 2021-10-20 | Bia Separations D.O.O. | A method of single-stranded rna purification |
| CN115715324A (zh) * | 2020-06-19 | 2023-02-24 | 伊泽阿恩埃免疫疗法股份有限公司 | Rna纯化方法 |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| WO2022101471A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Pharmaceutical compositions comprising lipid nanoparticles and mrna, and methods for preparing and storing the same |
| TW202237148A (zh) | 2020-11-16 | 2022-10-01 | 德商拜恩迪克公司 | 包含rna之lnp組合物以及製備、儲存及使用彼之方法 |
| WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CN115197935B (zh) * | 2021-04-08 | 2025-10-21 | 上海细胞治疗集团股份有限公司 | 纤维素色谱纯化rna的方法 |
| WO2022218891A2 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
| JP2024518335A (ja) | 2021-04-26 | 2024-05-01 | アンスティチュ パスツール | ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 |
| EP4355875A1 (en) * | 2021-06-14 | 2024-04-24 | 2seventy bio, Inc. | Single stranded rna purification methods |
| WO2022266389A1 (en) * | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
| CN113584014B (zh) * | 2021-07-27 | 2023-01-20 | 上海兆维科技发展有限公司 | 一种rna的制备方法、合成蛋白质的方法以及转录反应液 |
| KR20240042414A (ko) | 2021-07-29 | 2024-04-02 | 비온테크 에스이 | 흑색종의 치료용 조성물 및 방법 |
| WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| EP4398882A1 (en) | 2021-09-10 | 2024-07-17 | BioNTech SE | Lipid-based rna formulations suitable for therapy |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| EP4238577A3 (en) | 2021-10-22 | 2023-12-06 | BioNTech SE | Compositions for administration of different doses of rna |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| IL312557A (en) * | 2021-11-08 | 2024-07-01 | Gritstone Bio Inc | Self-amplifying RNA compounds and methods of using them |
| WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
| JP2025508332A (ja) | 2022-01-27 | 2025-03-26 | ビオンテック エスエー | 単純ヘルペスウイルス抗原の送達のための薬学的組成物及び関連方法 |
| JP2025508886A (ja) * | 2022-02-28 | 2025-04-10 | レヴィティ・ヘルス・サイエンシズ・インコーポレイテッド | 二本鎖及び一本鎖リボ核酸（ｒｎａ）を分離並びに検出する方法 |
| WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
| KR102994871B1 (ko) | 2022-04-01 | 2026-07-27 | 주식회사 엘지에너지솔루션 | 연성회로기판을 포함하는 파우치형 전지셀 |
| WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| AU2023268051A1 (en) | 2022-05-13 | 2025-01-02 | BioNTech SE | Rna compositions targeting hiv |
| CN114921457B (zh) * | 2022-05-16 | 2023-09-29 | 硅羿科技（上海）有限公司 | 一种提取dsRNA的方法 |
| WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| CA3260283A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions containing amphiphilic oligoethylene glycol (OEG) conjugated compounds and methods of using such compounds and compositions |
| IL318534A (en) | 2022-08-03 | 2025-03-01 | BioNTech SE | RNA for preventing or treating tuberculosis |
| WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| CN117660434A (zh) * | 2022-08-29 | 2024-03-08 | 国家纳米科学中心 | 从mRNA中去除dsRNA的方法和装置 |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| IL319414A (en) | 2022-09-23 | 2025-05-01 | BioNTech SE | Compositions for delivering antigens at the liver level and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| US20260151470A1 (en) | 2022-09-23 | 2026-06-04 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| CN120129702A (zh) | 2022-10-06 | 2025-06-10 | 生物技术公司 | 靶向密蛋白-18.2的rna组合物 |
| CN121127490A (zh) | 2022-12-28 | 2025-12-12 | 生物技术欧洲股份公司 | 靶向hiv的rna组合物 |
| WO2024153324A1 (en) | 2023-01-18 | 2024-07-25 | BioNTech SE | Rna formulations for pharmaceutical use |
| CN121002196A (zh) | 2023-02-28 | 2025-11-21 | 百欧恩泰欧洲股份公司 | 用于多种编码核酸的接头序列效力测定 |
| WO2024180363A1 (en) | 2023-02-28 | 2024-09-06 | BioNTech SE | Linker sequence potency assays for multiple coding nucleic acids |
| CN121127584A (zh) | 2023-03-09 | 2025-12-12 | 生物技术公司 | 具有杀细菌活性的肽聚糖水解酶 |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| EP4694920A1 (en) | 2023-04-14 | 2026-02-18 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024216212A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024213776A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| CN121038807A (zh) | 2023-05-03 | 2025-11-28 | 生物技术欧洲股份公司 | 优化的csp变体及相关方法 |
| WO2024230783A1 (zh) * | 2023-05-11 | 2024-11-14 | 中国科学院过程工程研究所 | 一种在体外转录过程中减少或抑制双链核糖核酸形成的mRNA高产制备方法及试剂盒 |
| WO2024236192A1 (en) | 2023-05-17 | 2024-11-21 | Institut Pasteur | Heterodimer of poxvirus a16 and g9 proteins as an immunogen |
| AU2024310564A1 (en) | 2023-06-29 | 2025-11-27 | BioNTech SE | Modular multiplatform system for mrna drug production |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| EP4746902A2 (en) | 2023-07-21 | 2026-05-27 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| EP4750488A1 (en) | 2023-07-24 | 2026-06-03 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025026866A1 (en) | 2023-07-28 | 2025-02-06 | BioNTech SE | Rna therapeutics with reduced toxicity |
| CN121866336A (zh) | 2023-08-03 | 2026-04-14 | 百欧恩泰欧洲股份公司 | 靶向hiv的rna组合物 |
| AU2024316307A1 (en) | 2023-08-03 | 2026-02-26 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| EP4754130A2 (en) | 2023-08-03 | 2026-06-10 | BioNTech SE | Rna compositions targeting hiv |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
| CN121844046A (zh) | 2023-09-11 | 2026-04-10 | C·米库尔卡 | 用于递送肠促胰岛素剂的rna组合物 |
| EP4527937A1 (en) | 2023-09-20 | 2025-03-26 | BioNTech SE | One-pot in vitro transcription of multiple dna molecules to multiple rna molecules |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| KR20260062985A (ko) | 2023-10-13 | 2026-05-07 | 스마트셀라 솔루션즈 아베 | 중간엽 줄기세포를 이용한 비변형 mRNA 작제물의 전달을 위한 방법 및 조성물 |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025133908A1 (en) * | 2023-12-20 | 2025-06-26 | Solventum Intellectual Properties Company | Method of separating nucleic acids |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025213131A1 (en) | 2024-04-05 | 2025-10-09 | BioNTech SE | Rna compositions for delivery of orthopox antigens and related methods |
| WO2025223684A1 (en) | 2024-04-23 | 2025-10-30 | BioNTech SE | Methods and compositions for stimulating immune response |
| TW202617177A (zh) | 2024-06-18 | 2026-05-01 | 德商拜恩技術股份公司 | 用於治療黑色素瘤之組合物及方法 |
| WO2026015882A1 (en) | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
| WO2026041793A1 (en) | 2024-08-23 | 2026-02-26 | BioNTech SE | Chimeric proteins comprising non-human protein domains for enhancing antigenicity |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026047153A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Potency assay for multiple coding nucleic acids |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026078207A1 (en) | 2024-10-11 | 2026-04-16 | Navigo Proteins Gmbh | Novel dsrna binding ligands and their use in affinity chromatography |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
| WO2026162682A1 (en) | 2025-01-29 | 2026-08-06 | BioNTech SE | Compositions for delivery of plasmodium rh5 antigens and related methods |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2936240A1 (de) * | 1979-09-07 | 1981-03-26 | Bayer Ag, 51373 Leverkusen | Verfahren zur herstellung bekannter und neuer 6-amino-6-desoxy-2,3-0-isopropyliden-(alpha)-l-sorbofuranose-derivate sowie neue zwischenprodukte des verfahrens |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| NL8900725A (nl) * | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| JP3692395B2 (ja) | 2000-09-01 | 2005-09-07 | 独立行政法人農業・生物系特定産業技術研究機構 | ベクターモノカリオンを用いた紫紋羽病菌に対するゲノムが２本鎖ｒｎａである糸状菌に寄生するウイルスを導入する新規方法 |
| US20050059024A1 (en) * | 2003-07-25 | 2005-03-17 | Ambion, Inc. | Methods and compositions for isolating small RNA molecules |
| US20050054847A1 (en) * | 2003-08-01 | 2005-03-10 | Invitrogen Corporation | Compositions and methods for preparing short RNA molecules and other nucleic acids |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| EP1996730A4 (en) * | 2006-03-08 | 2010-03-03 | Promega Corp | CLEANING OF SMALL RNA |
| CN101086011B (zh) * | 2006-06-08 | 2010-12-08 | 河南农业大学 | 食用菌和植物双链rna病毒检测试剂盒及其应用 |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| ES2769129T3 (es) | 2009-12-07 | 2020-06-24 | Univ Pennsylvania | Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células |
| DK3421601T3 (da) * | 2011-12-30 | 2020-02-24 | Cellscript Llc | Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt |
| DK3303583T3 (da) * | 2015-05-29 | 2020-07-13 | Curevac Real Estate Gmbh | Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering |
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
-
2017
- 2017-04-19 SI SI201730980T patent/SI3445850T1/sl unknown
- 2017-04-19 SG SG11201807573VA patent/SG11201807573VA/en unknown
- 2017-04-19 DK DK17722695.8T patent/DK3445850T3/da active
- 2017-04-19 ES ES17722695T patent/ES2900272T3/es active Active
- 2017-04-19 MA MA44732A patent/MA44732B1/fr unknown
- 2017-04-19 BR BR112018069417-7A patent/BR112018069417A2/pt not_active IP Right Cessation
- 2017-04-19 CN CN201780024328.9A patent/CN109072232B/zh active Active
- 2017-04-19 PL PL17722695T patent/PL3445850T3/pl unknown
- 2017-04-19 KR KR1020227009308A patent/KR102565881B1/ko active Active
- 2017-04-19 SG SG10202010471UA patent/SG10202010471UA/en unknown
- 2017-04-19 RS RS20211459A patent/RS62612B1/sr unknown
- 2017-04-19 LT LTEPPCT/EP2017/059293T patent/LT3445850T/lt unknown
- 2017-04-19 RU RU2018136601A patent/RU2760790C2/ru active
- 2017-04-19 HR HRP20211745TT patent/HRP20211745T1/hr unknown
- 2017-04-19 WO PCT/EP2017/059293 patent/WO2017182524A1/en not_active Ceased
- 2017-04-19 SM SM20210681T patent/SMT202100681T1/it unknown
- 2017-04-19 DK DK21204500.9T patent/DK4008782T3/da active
- 2017-04-19 CA CA3020481A patent/CA3020481A1/en active Pending
- 2017-04-19 US US16/091,389 patent/US20190153425A1/en not_active Abandoned
- 2017-04-19 MD MDE20190258T patent/MD3445850T2/ro unknown
- 2017-04-19 MX MX2018012880A patent/MX2018012880A/es unknown
- 2017-04-19 KR KR1020187030368A patent/KR102378404B1/ko active Active
- 2017-04-19 RU RU2021134269A patent/RU2021134269A/ru unknown
- 2017-04-19 AU AU2017251983A patent/AU2017251983B2/en active Active
- 2017-04-19 PT PT177226958T patent/PT3445850T/pt unknown
- 2017-04-19 NZ NZ745940A patent/NZ745940A/en unknown
- 2017-04-19 ES ES21204500T patent/ES3070087T3/es active Active
- 2017-04-19 HU HUE17722695A patent/HUE059314T2/hu unknown
- 2017-04-19 JP JP2018555164A patent/JP7000343B2/ja active Active
- 2017-04-19 EP EP21204500.9A patent/EP4008782B1/en active Active
- 2017-04-19 EP EP17722695.8A patent/EP3445850B2/en active Active
- 2017-04-19 EP EP26160566.1A patent/EP4756021A2/en active Pending
-
2018
- 2018-09-05 ZA ZA2018/05949A patent/ZA201805949B/en unknown
- 2018-10-11 IL IL262304A patent/IL262304B2/en unknown
-
2019
- 2019-08-22 ZA ZA2019/05536A patent/ZA201905536B/en unknown
-
2021
- 2021-11-26 CY CY20211101032T patent/CY1124845T1/el unknown
- 2021-12-23 JP JP2021209047A patent/JP7335313B2/ja active Active
-
2025
- 2025-08-22 US US19/307,372 patent/US20260071201A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3445850T3 (da) | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna | |
| IL261271A (en) | Methods for making l-glufosinate | |
| DK3433368T3 (da) | Transreplikerende rna | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| DK3134506T3 (da) | Fremgangsmåder til oprensning af messenger rna | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3294885T3 (da) | Fremgangsmåde til at fremstille rna | |
| DK3198035T3 (da) | Fremgangsmåder til forudsigelse af medicinrespons | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| DK3402773T3 (da) | Fremgangsmåde til fremstilling af methanol | |
| DK3728585T3 (da) | Hidtil ukendte fremgangsmåder til fremstilling af oligonukleotider | |
| DK3359281T3 (da) | Fremgangsmåde til udtrækning af CO2 | |
| DK3789042T3 (da) | Fremgangsmåde til fremstilling af anti-her3-antistof-lægemiddelkonjugat | |
| DK3473621T3 (da) | Fremgangsmåde til fremstilling af diphenylmethan-derivat | |
| DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
| DK3344805T3 (da) | Fremgangsmåde til udvælgelse af aptamerer til ubundne mål | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3314010T3 (da) | Fremgangsmåde til detektering af kromosomaberrationer | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK4235628T3 (da) | System til frembringelse af en omgivelse | |
| DK3114235T3 (da) | Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet | |
| DK3430072T3 (da) | Fremgangsmåde til oprensning af poloxamerer |